Ocular Therapeutix, Inc. ads

Age-related macular degeneration (AMD) can be hereditary, leaving many patients concerned not only about their own vision but also the eye health of their children and grandchildren. This risk can make the future feel uncertain, underscoring the need for improved treatment options. That’s why treatment innovation matters. At Ocular, we’re committed to advancing research beyond today's treatments as we aim to redefine the retina experience for generations to come. Learn more about retinal disease, including wet AMD: https://ow.ly/SKST50XAELY #WetAMD #RetinaRedefined Reference: Gehrs KM, et al. 𝘈𝘯𝘯 𝘔𝘦𝘥. 2006;38(7):450-471.

Today, Ocular Therapeutix, Inc. is advancing our mission to redefine the retina experience for patients with retinal disease worldwide. Diabetic retinopathy remains a leading cause of vision loss, impacting nearly 9 million working adults in the U.S. alone. The current burden is significant; balancing work, family obligations, and other conditions creates major challenges that make it difficult for patients to maintain treatment. With the launch of the HELIOS-3 trial for non-proliferative diabetic retinopathy, Ocular aims to deliver a sustainable treatment option that reduces treatment burden while empowering patients to maintain their vision and independence. I'm proud of our team's relentless commitment to transform what's possible for those affected by retinal disease. Learn more about this milestone: https://lnkd.in/edcd9iqN #HELIOS #DiabeticRetinopathy #RetinaRedefined

Ocular is excited to announce the initiation of our HELIOS-3 Phase 3 trial for non-proliferative diabetic retinopathy (NPDR), a leading cause of vision loss in the working-age population. This trial represents a key step toward delivering a potentially sustainable, long-lasting treatment that could transform care for patients with diabetic retinopathy. We’re thankful for the team, investigators, patients, and care partners who make our work possible. This milestone advances our ongoing mission to redefine the retina experience. You can read more at https://ow.ly/YLwU50XwNq4. #HELIOS #DiabeticRetinopathy #RetinaRedefined

If you notice a change in your vision, it’s important to see your eye care provider. Timely care can make a meaningful difference in managing retinal disease like wet age-related macular degeneration (AMD). We’re redefining the retina experience by working to develop innovative treatments for patients, like Julia, that aim to reduce the treatment burden and preserve vision for the long term. Learn more: https://ow.ly/E4lx50XkVq8 #WetAMD #Retina #RetinaRedefined Reference: Seluarize G, et al. 𝘊𝘶𝘳𝘦𝘶𝘴. 2023;15(6):e41169.

The first-time presentation of positive data from our landmark SOL-1 Phase 3 superiority trial in wet age-related macular degeneration will take place at Macula Society, alongside an update on our HELIOS program in non-proliferative diabetic retinopathy. We’re excited to hear from Drs. Mark Barakat, Dilsher Dhoot, Arshad M. Khanani, Patricio Schlottmann, and Adnan Tufail on the significance of these results and what they could mean for the future of retinal disease care as we work to redefine the retina experience. #MaculaSociety #RetinaRedefined

Spending time together as a team at the American Academy of Ophthalmology (AAO) Annual Meeting and Eyecelerator in Orlando gave us more than just a chance to share our work at Ocular—it gave us space to reconnect and reflect. We also heard from our Chief Development Officer, Peter Kaiser, MD, who spotlighted Ocular's latest advancements and strategic direction, and our Chief Scientific Officer, Jeff Heier, MD, during The 2025 Debates—a forum that brought together leading voices to discuss the future of ophthalmology. We left Orlando energized to continue working towards our mission to redefine the retina experience. #AAO2025 #Eyecelerator #RetinaRedefined